|Celularity Inc., of Florham Park, N.J.||CYNK-001||Non-genetically modified cryopreserved human placental hematopoietic stem cell-derived NK cell therapy||Recurrent glioblastoma multiforme||FDA granted fast track designation|
|Chinese Academy of Sciences’ Institute of Microbiology, of Beijing||Recombinant protein subunit vaccine||Recombinant protein subunit vaccine||COVID-19||Approved in China for emergency use|
|Peptomyc SL, of Barcelona, Spain||Omomyc (OMO-103)||Myc inhibitor||Solid tumors||Received approval from Spanish Agency of Medicines and Medical Devices to conduct phase I/II study|
|Precigen Inc., of Germantown, Md.||PRGN-2012||Off-the-shelf Adenoverse immunotherapy||Recurrent respiratory papillomatosis||FDA granted orphan designation|
|Sangamo Therapeutics Inc., of Brisbane, Calif., and Sanofi SA, of Paris||BIVV-003||Ex vivo gene-edited cell therapy||Sickle cell disease||EMA’s Committee for Orphan Medicinal Products released details supporting orphan designation|
For more information about individual companies and/or products, see Cortellis.